Clonidine in Attention Deficit Hyperactivity Disorder (ADHD) in Children

Attention Deficit Disorder With Hyperactivity Clinical Trial

Official title:

Clonidine in Attention Deficit Hyperactivity Disorder (ADHD) Treatment (CAT)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00031395
• Other study ID #: R01NS039087
• Status: Completed
• Phase: Phase 3
• First received: March 4, 2002
• Last updated: May 20, 2009
• Start date: September 1999
• Est. completion date: June 2007

Study information

• Verified date: May 2009
• Source: University of Cincinnati
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Federal GovernmentUnited States: University of Cincinnati IRB
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine the safety and efficacy of clonidine alone or in combination with methylphenidate for children 7-12 years of age with attention-deficit, hyperactivity disorder.

Description:

This trial will compare the benefits and side effects of two medications-clonidine and methylphenidate (MPH)-used alone or in combination to treat ADHD in children. MPH is FDA-approved for the treatment of ADHD symptoms in children, and clonidine is FDA-approved for the treatment of hypertension in adults. Stimulant medications such as MPH are known to be safe and effective for the treatment of many ADHD symptoms. Such medicines, however, do not cure the condition or improve all of the symptoms of ADHD, and the long-term effectiveness of these medications is not well-known. In this study the participants will be randomly selected to receive one of four treatments: 1.) clonidine; 2.) MPH; 3.) clonidine and MPH; or 4.) a placebo (which is not an active medication, but a substance that is thought to have no biological effect). The time participation in the study is 16 weeks.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 122
• Est. completion date: June 2007
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 7 Years to 12 Years

Eligibility

Inclusion Criteria:

• Children aged 7 through 12 in school.

• All subjects must meet DSM IV criteria for the diagnosis of ADHD of any subtype [21].

• Each subject must also satisfy the following criteria regarding the severity of ADHD symptoms: 1. ADHD must be viewed as clinically significant and worthy of treatment by medications as judged by the parent and the site investigator. Operationally, medication treatment will be considered indicated for any subject who has ADHD symptoms that significantly interfere with academic or social functioning and that have not improved (or are not expected to improve) sufficiently with non-pharmacological interventions (e.g., modifying the classroom environment, tutoring). 2. The site investigator's rating of global functioning on the C-GAS must yield a score of 70 or below. Scores below 70 on the C-GAS are designated as indicating abnormal function [22]. The score of 70 corresponds to the anchor point description: "Some difficulty in a single area, but generally functioning pretty well."

• Screen of Intelligence using the vocabulary and block design subtests of the Wechsler Intelligence Scale for Children-Third Edition indicates an estimated I.Q > 70.

• Informed consent/assent signed. We will not enroll any child who does not want to participate.

• The designated school for each subject agrees to participate in the study by completing all required questionnaires and following all specified procedures.

• The child must be able to swallow the tablets and capsules used in this study.

Exclusion Criteria:

• Subjects with tic disorder of any type or tic symptoms, a primary diagnosis of major depression, pervasive developmental disorder, autism, any psychotic disorder, and mental retardation (based on current DSM criteria) will be excluded. We will not exclude subjects with obsessive-compulsive disorder, oppositional-defiant disorder or conduct disorder.

• The presence of a known medical condition that would preclude the use of MPH or clonidine.

• Known pregnancy. A urinary pregnancy test will be performed for all menstruating female subjects. Female subjects of child bearing potential will be advised not to become pregnant. In this circumstance, study medication will be tapered and discontinued and the subject will be terminated from the study. A urinary pregnancy test will be repeated at the end of the study. Subjects who request information regarding possible birth control mechanisms will be referred to their primary care physicians.

• Known presence of impaired renal function. A routine urinalysis will be performed for each subject to exclude signs of renal failure.

• Known active cardiovascular disease/anomaly, which would be a contraindication for the use of MPH or clonidine.

• Subjects may not receive any other medication for the treatment of ADHD. Treatment with MPH or other stimulants must be discontinued for at least 2 weeks prior to enrollment and treatment with other medications to treat ADHD (e.g., antidepressants, clonidine) must be discontinued for at least 6 weeks prior to enrollment.

• Subjects may not receive any other psychotropic medication (e.g., serotonin reuptake inhibitors), anxiolytics (e.g., clonazepam) or hypnotics. Any such medication must be discontinued at least 6 weeks prior to enrollment.

• Previous use of MPH or clonidine will be permitted.

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Attention Deficit Disorder With Hyperactivity
• Hyperkinesis

Intervention

Drug:
• clonidine
Clonidine is FDA-approved for the treatment of hypertension in adults.
• methylphenidate
MPH is FDA-approved for the treatment of ADHD symptoms in children.

Other:
• placebo
an inactive substance

Locations

Country	Name	City	State
United States	SUNY Buffalo, Center For Children & Families	Buffalo	New York
United States	Children's Hospital Medical Center	Cincinnati	Ohio
United States	Western Psychiatric Institute and Clinic	Pittsburgh	Pennsylvania
United States	University of Rochester, Department of Neurology	Rochester	New York

Sponsors (2)

Lead Sponsor	Collaborator
University of Cincinnati	National Institute of Neurological Disorders and Stroke (NINDS)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Efficacy outcome was change in score on the Conners Abbreviated Symptom Questionnaire for Teachers (ASQ-T)		at 16 weeks	No
Secondary	the ASQ-Parent (ASQ-P) and Child Global Assessment Scales (C-GAS). Adverse events were monitored using AE logs, the Pittsburgh Side Effects Rating Scale, vital signs and electrocardiograms		at 16 weeks	No